House Democrats ask pharma CEOs to explain insulin pricing

House Democrats Wednesday asked Eli Lilly and Co. (NYSE:LLY), Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Sanofi (NASDAQ:SNY; Euronext:SAN) to justify all insulin product price increases over the past decade and disclose any deals that may have inhibited generic availability.

"Despite the fact that it has been available for decades, prices for insulin have skyrocketed in recent years, putting it out of reach for many patients,” Committee on Energy and Commerce Chairman Frank Pallone (D-N.J.) said in a statement...